Management of endometriosis with oral medroxyprogesterone acetate

Obstet Gynecol. 1976 Mar;47(3):265-7.

Abstract

Efficacy of oral medroxyprogesterone acetate (MPA) was assessed in 35 women with an established diagnosis of endometriosis (33 pelvic and 2 abdominal). MPA was given in a dosage of 30 mg daily for 90 days. Results indicated improvement or remission in all cases, even though breakthrough bleeding occurred in 8. Twenty-six were treated for associated infertility. Twelve of these became pregnant following treatment. Pregnancy rate in those women whose husbands were fertile was 90%. Side effects included spotting and breakthrough bleeding. The patients usually remained amenorrheic and anovulatory while receiving MPA. Posttreatment resumption of ovulation was prompt. The findings indicate that oral MPA is a useful therapeutic agent in the management of minimal to moderate endometriosis, particularly when it is associated with infertility.

MeSH terms

  • Abdominal Neoplasms / drug therapy*
  • Administration, Oral
  • Endometriosis / drug therapy*
  • Female
  • Humans
  • Male
  • Medroxyprogesterone / administration & dosage
  • Medroxyprogesterone / adverse effects
  • Medroxyprogesterone / therapeutic use*
  • Pelvic Neoplasms / drug therapy*
  • Pregnancy
  • Progesterone / blood

Substances

  • Progesterone
  • Medroxyprogesterone